3.1.2 Exenatide As the first GLP-1R agonist approved for T2DM, EX is a new class of compound and a synthetic product of exendin-4, which is a compound naturally derived from the Gila monster and has multiple hypoglycemic mechanisms: inhibiting of glucagon release from cells, slowing of gastric emptying, decreasing appetite and increasing glucose-dependent insulin secretion ( Lipotoxicity induced by saturated free fatty acids plays a vital role in renal injury in obese patients ( There is little research on the weight loss effect of EX on simple obesity patients, and more clinical trials are conducted on patients with T2DM
In practice, clinicians have been using these for over a decade (liraglutide was approved in 2010 for diabetes, 2014 for obesity
Some antibiotics, particularly fluoroquinolones, can cause unpredictable glucose fluctuations that may require closer monitoring or temporary adjustment of diabetes medications
Activation there reduces food intake, and it is this central action, as much as any peripheral effect, that drives the weight loss seen with GLP-1 drugs
It's important to understand that immediate results are not to be expected after a single dose